Evaluation of RNA-sequencing (RNA-seq) signatures with pembrolizumab (pembro) in patients (pts) with renal cell carcinoma (RCC) from KEYNOTE-427 cohort A.

David F. McDermott,Jae-Lyun Lee,Georg A. Bjarnason,James Larkin,Rustem Gafanov,Mark D. Kochenderfer,Jahangeer Malik,Alexandr Poprach,Scott S. Tykodi,Sabina Signoretti,Rodolfo F. Perini,Jared Lunceford,Raluca Andreia Predoiu,Andrey Loboda,Qing Zhao,Alexandra Snyder,Charles Schloss,Michael B. Atkins

Evaluation of RNA-sequencing (RNA-seq) signatures with pembrolizumab (pembro) in patients (pts) with renal cell carcinoma (RCC) from KEYNOTE-427 cohort A.

2020

David F. McDermott
Jae-Lyun Lee
Georg A. Bjarnason
James Larkin
Rustem Gafanov
Mark D. Kochenderfer
Jahangeer Malik
Alexandr Poprach
Scott S. Tykodi
Sabina Signoretti
Rodolfo F. Perini
Jared Lunceford
Raluca Andreia Predoiu
Andrey Loboda
Qing Zhao
Alexandra Snyder
Charles Schloss
Michael B. Atkins

729Background: We evaluated the association (assoc) of baseline RNA-seq–based signatures with response/resistance to pembro from the phase 2 KEYNOTE-427 study (NCT02853344) in pts with advanced cle...

Keywords:

Pathology
Cohort
Oncology
RNA
Internal medicine
RNA-Seq
Renal cell carcinoma
Pembrolizumab
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations